Clinico-pathological associations and concomitant mutations of the RAS/RAF pathway in metastatic colorectal cancer

被引:0
作者
Edoardo Isnaldi
Anna Garuti
Gabriella Cirmena
Stefano Scabini
Edoardo Rimini
Lorenzo Ferrando
Michela Lia
Roberto Murialdo
Lucia Tixi
Enrico Carminati
Andrea Panaro
Maurizio Gallo
Federica Grillo
Luca Mastracci
Lazzaro Repetto
Roberto Fiocca
Emanuele Romairone
Gabriele Zoppoli
Alberto Ballestrero
机构
[1] University of Genoa,Department of Internal Medicine (Di.M.I.)
[2] University of Genoa,Department of Integrated Surgical and Diagnostic Sciences (DISC)
[3] Ospedale Policlinico San Martino IRCCS Per l’Oncologia,Department of Oncology
[4] Ospedale Civile “G Borea”,undefined
来源
Journal of Translational Medicine | / 17卷
关键词
Metastatic colorectal cancer; Extended RAS; RAS/RAF pathway; Anti-EGFR; Concomitant mutations;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 241 条
[31]  
Pietrantonio F(2016)Genetic heterogeneity in synchronous colorectal cancers impacts genotyping approaches and therapeutic strategies Genes Chromosom Cancer 55 268-1848
[32]  
Petrelli F(2016)The influence of subclonal resistance mutations on targeted cancer therapy Nat Rev Clin Oncol 13 335-1729
[33]  
Coinu A(2016)BRAF and NRAS locus specific variants have different outcomes on survival to colorectal cancer Clin Cancer Res. 23 2742-1964
[34]  
Di Bartolomeo M(2015)Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance Oncotarget. 6 20785-2092
[35]  
Borgonovo K(2013)Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients Cancer Genet 206 330-1801
[36]  
Maggi C(2013)The prognostic role of KRAS, BRAF, PIK3CA and PTEN in colorectal cancer Br J Cancer 108 2153-233
[37]  
Sartore-Bianchi A(2016)Prognostic role of tumor PIK3CA mutation in colorectal cancer: a systematic review and meta-analysis Ann Oncol 27 1836-830
[38]  
Martini M(2017)Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials Ann Oncol 28 1713-undefined
[39]  
Molinari F(2006)Type, density, and location of immune cells within human colorectal tumors predict clinical outcome Science 313 1960-undefined
[40]  
Veronese S(2018)Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer N Engl J Med 378 2078-undefined